Global Pharmacogenomics Market – Overview
The pharmacogenomics market value is growing at an incremental pace of development on the global stage due to the large number of advantages associated to personalized therapy. Market Research Future, a firm which specializes in market reports related to the healthcare sector among others, recently forecasted in its report on the pharmacogenomics market is expected to reach USD 6,670.3 Million by 2030 at 8.52% CAGR during the forecast period 2022-2030. Pharmacogenomics is one of the essential elements in personalized medicine. The simple concept in pharmacogenomics is that interindividual variability in drug response is a consequence of multiple factors, including genomics, epigenomics, the environment and a patient's characteristics, such as gender, age and/or concomitant medication.
Global Pharmacogenomics Market - Competitive Analysis
Pharmacogenomics in recent years has used a new generation of technology approaches that has led to a revolution in the understanding of disease susceptibility and pathophysiology, providing enormous potential for novel therapeutic strategies.
However, with companies aiming to capture a considerable share of the market segment as early as possible, they are competing and experimenting with various advantage points. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in the best strategies.
The Pharmacogenomics Market Players report includes Myriad Genetics, Inc. (U.S.), 23andMe, Inc. (U.S.), Pathway Genomics (U.S.), GeneTech (U.S.), GeneDx. (U.S.), Future Science Group (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Assurex Health, Inc. (U.S.), OneOme (U.S.) and others.
Segmentation
The global pharmacogenomics market is segmented on the basis of technology, application, and end user.
On the basis of technology, the market is segmented into microarray, sequencing, polymerase chain reaction, and others. The sequencing segment is sub-segmented into Sanger sequencing, pyrosequencing, next-generation sequencing, and others.
On the basis of application, the market is segmented into oncology, cardiology, neurological disorders, and others. The oncology segment, by technology, is sub-segmented into breast cancer, lung cancer, and others.
On the basis of end users, the market is segmented into hospitals, research organizations, academic institute, and others
Global Pharmacogenomics Market - Regional Analysis
The global pharmacogenomics market is segmented into Americas, Europe, Asia Pacific and the Middle East Africa. Global pharmacogenomics market is highly dominated by North America and Europe due to majority of pharmaceutical companies engaged in research development activities, increasing awareness about side effects of a drug among the people, production of next generation PCR technology and microarray system which drive the growth of this market. APAC is fastest growing region due to the presence of a huge patient population, continuously developing economies like India and China and presence of huge opportunities drives the market growth. For instance, According to the Indian Brand Equity Foundation in 2016, the Indian biotech industry is estimated to reach USD 100 billion by 2025 from USD 7.0 billion in 2015.
Latest Industry Updates
Nov 2017: Myriad Genetics, Inc., announced positive results from a double-blind, multi-center, randomized controlled trial assessing the impact of the GeneSight Psychotropic test (GeneSight) on psychiatric treatment response in 1,200 patients with major depressive disorder. GeneSight is one of the leading pharmacogenomics test to help guide medication selection for mental health disorders.
June 2016: OneOme announced about key business milestones in advance of launching its RightMed test. RightMed test is a cost-effective, comprehensive, personalized pharmacogenomics product which analyses 22 genes which provided at the point of care. The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme’s RightMed test is currently in use by Mayo Clinic Center for individualized medicine. The test helps providers easily make personalized treatment decisions across more than 300 medications for more than 20 medical indications.
About US:
Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
